Figure 4. Conventional APCs are not required for CD8⁺ T cell-dependent tumor control.

(A) A20-bearing CD11c-DTR-reconstituted BALB/c mice (n = 5/group) were injected subcutaneously (s.c.) with A20 cells (1 × 10⁷) and treated intratumorally (i.t.) with 3 μg of anti-CD20-IFNα or control hIgG on days 18 and 21. DT was administered every two days starting on day 17. (B) Approximately 45 days after the tumor rejection from (A), the mice were rechallenged with A20 cells (3 × 10⁷). Naïve WT BALB/c mice were used as the control. (C) WT BALB/c mice (n = 8/group) were injected s.c. with A20 cells (3 × 10⁶) and treated i.t. with 3 μg of anti-CD20-IFNα or control hIgG on day 10. The macrophage-depleting reagent (Clophosome, 200 μg/mouse) or control liposome was administered intraperitoneally (i.p.) on days 9 and 12. (D) Approximately 45 days after the tumor rejection in (C), the mice were rechallenged with A20 cells (1.5 × 10⁷). Naïve WT BALB/c mice were used as the control. (E) A20-bearing CD11c-DTR-reconstituted BALB/c mice (n = 5/group) were injected s.c. with 1 × 10⁷ A20 cells and treated i.t. with 3 μg of anti-CD20-IFNα or control hIgG on days 10 and 13. DT was administered i.p. on days 9, 11, and 13. Clophosome (200 μg/mouse) or control liposome was administered i.p. on days 9 and 13. (F) μMT^−/− BALB/c mice (n = 6/group) were injected s.c. with A20 cells (3 × 10⁶) on the right flank and treated i.t. with 3 μg of anti-CD20-IFNα or control hIgG on days 10 and 12. Data represent mean ± SEM of two independent experiments. ***P < 0.001.